PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Mirikizumab sustains multidomain UC remission through four years

Provides the first long-term extension data pairing durable endoscopic and histologic remission with corticosteroid-sparing and bowel-urgency outcomes for an anti-IL-23 p19 agent in ulcerative colitis.
📅 Journal publication: Jun 1, 2026 · Last updated: Jul 16, 2026
mirikizumabinterleukin-23 p19 inhibitorulcerative colitisbiologic maintenancecorticosteroid-sparingopen-label extensionLUCENT-3endoscopic remissionhistologic remission Gastroenterology / Hepatology

Background Information

Four-year study shows lasting ulcerative colitis remission with mirikizumab.

Sustained long-term treatment is crucial for managing chronic conditions like ulcerative colitis. Mirikizumab maintained remission in high percentages, with 77.7% clinical remission at 212 weeks. This study supports mirikizumab’s long-term efficacy and safety, vital for patients with previous biologic failure. Mirikizumab offers durable control in ulcerative colitis over four years.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Sands BE, Clemow DB, D'Haens G, Irving PM, Kobayashi T, Peyrin-Biroulet L, Samaan K, Gaur A, Arora R, Todd K, Moses R, Dignass A

Citation: Sands BE, Clemow DB, D'Haens G, et al. Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study. Inflammatory bowel diseases. 2026;32(6):1023-1040. doi:10.1093/ibd/izag007

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Suggest a correction Request a topic
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.